MedTrace Logo

Modified Psychodynamic Psychotherapy for Patients With Schizophrenia

NCT02576613 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2024-02-06

No results posted yet for this study

Summary

A randomized controlled, prospective, two-armed, mono-centric, assessor-blinded clinical trial will serve to generate preliminary data on the efficacy and safety of modified psychodynamic therapy (MPP-S) in stabilized patients after the first or subsequent episodes of schizophrenia or schizoaffective disorder.

Conditions

Interventions

OTHER

MPP-S

\> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment

OTHER

TAU

standard medical treatment without structured psychotherapeutic intervention

Sponsors & Collaborators

  • International Psychoanalytic University Berlin

    collaborator OTHER

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Christiane Montag, MD · Charite University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02576613 on ClinicalTrials.gov